Company Performance - Darden Restaurants Inc. reported fourth-quarter adjusted earnings per share of $2.98, exceeding the analyst consensus estimate of $2.97 [2] - The company's quarterly sales reached $3.27 billion, surpassing the analyst consensus estimate of $3.26 billion [2] - For fiscal 2026, Darden expects adjusted EPS between $10.50 and $10.70, which is below the consensus estimate of $10.75 [2] - Darden projects total sales growth of 7% to 8% for the year [2] Stock Movements - Gorilla Technology Group Inc. shares increased by 36% to $25.51 following a strong first-quarter earnings report indicating significant revenue growth and a return to profitability [8] - Couchbase, Inc. shares surged 30% to $24.69 after agreeing to be acquired by Haveli Investments for $1.5 billion [8] - Innovative Eyewear, Inc. shares rose by 81% to $4.12 after announcing a partnership with Smartech Retail Group [8] - Accenture plc shares fell by 6% to $287.53 after releasing its third-quarter results [8] - Moleculin Biotech, Inc. shares dropped 47% to $0.31 due to a $5.9 million public offering announcement [8] - Smith & Wesson Brands, Inc. shares declined by 18% to $8.89 after reporting worse-than-expected fourth-quarter EPS and sales [8]

Company Performance - Accenture Plc reported third-quarter earnings of $3.49 per share, exceeding the analyst consensus estimate of $3.31 [2] - The company achieved sales of $17.7 billion, slightly above the analyst consensus estimate of $17.30 billion, with an 8% increase in U.S. dollars and a 7% increase in local currency [2] - Accenture narrowed its fiscal year 2025 revenue growth outlook to 6%-7% in local currency, up from a prior range of 5%-7% [3] - The company forecasts diluted earnings for 2025 to be between $12.77 and $12.89 per share, compared to the previous estimate of $12.55-$12.79 and the consensus of $12.75 [3] Market Movements - Wheeler Real Estate Investment Trust, Inc. shares surged 159% to $8.85 following the announcement of a 1-for-7 reverse stock split [9] - Dragonfly Energy Holdings Corp. shares increased by 74% to $0.3796 after a 6% gain on Wednesday [9] - Innovative Eyewear, Inc. shares rose 73% to $3.9502 after announcing a partnership with Smartech Retail Group [9] - Nature Wood Group Limited shares dropped 59% to $2.2950 after a previous surge of over 142% [9] - Moleculin Biotech, Inc. shares fell 48% to $0.3040 due to a $5.9 million public offering announcement [9] - Regencell Bioscience Holdings Limited shares decreased by 48% to $32.99 after a decline of over 18% on Wednesday [9]

Core Insights - Moleculin Biotech, Inc. announced that an abstract regarding its next-generation anthracycline, Annamycin, has been selected for poster presentation at the AACR Annual Meeting 2025 [1][2] Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat cancers and viruses [3] - The lead program, Annamycin, is designed to avoid multidrug resistance and eliminate cardiotoxicity associated with current anthracyclines, targeting relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases [3] Clinical Trials - The company is initiating the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML [4] - Following a successful Phase 1B/2 study, the company believes it has de-risked the development pathway towards potential approval for Annamycin [4] Additional Developments - Moleculin is also developing WP1066, an immune/transcription modulator targeting brain tumors and other cancers, and a portfolio of antimetabolites including WP1122 for treating pathogenic viruses and certain cancer indications [5]